Genmab A/s Share Price Today
(NASDAQ: GMAB)

Name: Genmab A/s Share Price Today (NASDAQ: GMAB) - Genmab A/s Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Genmab A/s share price is $19.67 & ₹1,704.21 as on 1 Feb 2025, 2.30 'hrs' IST

$19.67

▲

-0.14

(-0.71%)

Market is closed - opens 8 PM, 03 Feb 2025

View live Genmab A/s share price in Dollar and Rupees. Guide to invest in Genmab A/s stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Genmab A/s, along with analyst recommendations, forecasts, and comprehensive financials.

Genmab A/s share price movements

Today's Low: $19.62
Today's High: $19.97
$19.67
0.28%
Downside
Day's Volatility :1.77%
Upside
1.49%
52 Weeks Low: $19.02
52 Weeks High: $31.88
$19.67
3.3%
Downside
52 Weeks Volatility :40.34%
Upside
38.3%

Genmab A/s (GMAB) Returns

Period	Genmab A/s	Sector (Health Care)	Index (Russel 2000)
3 Months	-13.65%	-0.6%	0.0%
6 Months	-24.55%	-2.8%	0.0%
1 Year	-29.24%	3.3%	0.0%
3 Years	-43.35%	11.6%	-13.7%

Genmab A/s (GMAB) Key Statistics

in dollars & INR

Previous Close	$19.81
Open	$19.78
Today's High	$19.9679
Today's Low	$19.615
Market Capitalization	$12.6B
Today's Volume	$1.3M
52 Week High	$31.88
52 Week Low	$19.02
Revenue TTM	$19.8B
EBITDA	$6.9B
Earnings Per Share (EPS)	$1.01
PE Ratio	19.61
Profit Margin	23.7%
Quarterly Earnings Growth YOY	-0.38%
Return On Equity TTM	14.92%

How to invest in Genmab A/s Stock (GMAB) from India?

It is very easy for Indian residents to invest directly in Genmab A/s from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Genmab A/s stock in both Indian Rupees (INR) and US Dollars (USD). Search for Genmab A/s or GMAB on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Genmab A/s or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Genmab A/s shares which would translate to 0.044 fractional shares of Genmab A/s as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Genmab A/s, in just a few clicks!

Returns in Genmab A/s (GMAB) for Indian investors in Rupees

The Genmab A/s stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

Investment Value

₹1,00,000

Genmab A/s investment value today

Current value as on today

₹75,315

Returns

₹24,685

(-24.69%)

Returns from Genmab A/s Stock

₹29,245 (-29.24%)

Dollar Returns

₹4,559 (+4.56%)

Indian investors sentiment towards Genmab A/s (GMAB)

-48%

Period: Jan 1, 2025 to Jan 31, 2025. Change in 30 Days versus previous period

Search interest for Genmab A/s Stock from India on INDmoney has decreased by -48% in the last 30 days, reflecting a downward trend in search activity.

Global Institutional Holdings in Genmab A/s

AllianceBernstein L.P.
2.38%
BlackRock Inc
0.73%
Capital Research & Mgmt Co - Division 3
0.70%
Harding Loevner L.P.
0.48%
Wellington Management Company LLP
0.36%
Renaissance Technologies Corp
0.28%

Analyst Recommendation on Genmab A/s

Buy

61%Buy

29%Hold

9%Sell

Based on 31 Wall street analysts offering stock ratings for Genmab A/s(by analysts ranked 0 to 5 stars)

Based on 31 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Genmab A/s Stock (GMAB)

What analysts predicted

Upside of 81.61%

Target:

$35.72

Current:

$19.67

Insights on Genmab A/s Stock (Ticker Symbol: GMAB)

Price Movement
In the last 7 days, GMAB stock has moved down by -6.9%
Increasing Revenue
Revenue is up for the last 3 quarters, 4.14B → 5.54B (in $), with an average increase of 12.9% per quarter
Decreasing Net Profit
Netprofit is down for the last 2 quarters, 1.40B → 1.26B (in $), with an average decrease of 10.1% per quarter
GMAB vs ALNY (1 yr)
In the last 1 year, Alnylam Pharmaceuticals, Inc. has given 55.1% return, outperforming this stock by 85.3%
GMAB vs VRTX (3 yr)
In the last 3 years, Vertex Pharmaceuticals Incorporated has given 87.2% return, outperforming this stock by 130.4%
Price to Sales
ForGMAB every $1 of sales, investors are willing to pay $0.6, whereas for Alnylam Pharmaceuticals, Inc., the investors are paying $16.4 for every $1 of sales.

GMAB Genmab A/s Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$461.0M	↑ 27.89%
Net Income	$224.3M	↑ 33.4%
Net Profit Margin	48.66%	↑ 2.01%

	FY19	Y/Y Change
Revenue	$798.0M	↑ 77.38%
Net Income	$322.1M	↑ 47.13%
Net Profit Margin	40.37%	↓ 8.29%

	FY20	Y/Y Change
Revenue	$1.7B	↑ 88.43%
Net Income	$777.7M	↑ 119.67%
Net Profit Margin	47.06%	↑ 6.69%

	FY21	Y/Y Change
Revenue	$1.3B	↓ 16.11%
Net Income	$449.5M	↓ 37.85%
Net Profit Margin	34.86%	↓ 12.2%

	FY22	Y/Y Change
Revenue	$2.1B	↑ 72.07%
Net Income	$775.6M	↑ 84.38%
Net Profit Margin	37.36%	↑ 2.5%

	FY23	Y/Y Change
Revenue	$2.4B	↑ 12.87%
Net Income	$637.3M	↓ 20.18%
Net Profit Margin	26.42%	↓ 10.94%

	Q2 FY23	Q/Q Change
Revenue	$611.0M	↑ 47.09%
Net Income	$197.5M	↑ 546.19%
Net Profit Margin	32.32%	↑ 24.96%

	Q3 FY23	Q/Q Change
Revenue	$679.2M	↑ 13.01%
Net Income	$304.8M	↑ 56.89%
Net Profit Margin	44.88%	↑ 12.56%

	Q4 FY23	Q/Q Change
Revenue	$685.1M	↓ 1.39%
Net Income	$93.7M	↓ 69.94%
Net Profit Margin	13.68%	↓ 31.2%

	Q1 FY24	Q/Q Change
Revenue	$603.9M	↓ 11.44%
Net Income	$193.1M	↑ 107.03%
Net Profit Margin	31.98%	↑ 18.3%

	Q2 FY24	Q/Q Change
Revenue	$779.3M	↑ 30.39%
Net Income	$203.1M	↑ 6.26%
Net Profit Margin	26.06%	↓ 5.92%

	Q3 FY24	Q/Q Change
Revenue	$5.5B	↑ 2.55%
Net Income	$1.3B	↓ 10.09%
Net Profit Margin	22.85%	↓ 3.21%

	FY18	Y/Y Change
Profit	$461.0M	↑ 27.89%

	FY19	Y/Y Change
Profit	$798.0M	↑ 77.38%

	FY20	Y/Y Change
Profit	$1.7B	↑ 88.43%

	FY21	Y/Y Change
Profit	$1.3B	↓ 16.11%

	FY22	Y/Y Change
Profit	$2.1B	↑ 72.07%

	FY23	Y/Y Change
Profit	$2.4B	↑ 11.33%

	Q2 FY23	Q/Q Change
Profit	$611.0M	↑ 47.09%

	Q3 FY23	Q/Q Change
Profit	$664.9M	↑ 10.62%

	Q4 FY23	Q/Q Change
Profit	$666.6M	↓ 1.98%

	Q1 FY24	Q/Q Change
Profit	$576.9M	↓ 13.05%

	Q2 FY24	Q/Q Change
Profit	$751.9M	↑ 31.68%

	Q3 FY24	Q/Q Change
Profit	$5.3B	↑ 1.06%

	FY18	Y/Y Change
Operating Cash Flow	$154.6M	↓ 36.14%
Investing Cash Flow	$-270.9M	↑ 166.34%
Financing Cash Flow	$-10.8M	↓ 132.99%

	FY19	Y/Y Change
Operating Cash Flow	$197.2M	↑ 30.67%
Investing Cash Flow	$-294.9M	↑ 11.53%
Financing Cash Flow	$544.3M	↓ 5262.13%

	FY20	Y/Y Change
Operating Cash Flow	$1.1B	↑ 385.14%
Investing Cash Flow	$-384.3M	↑ 18.56%
Financing Cash Flow	$11.6M	↓ 98.06%

	FY21	Y/Y Change
Operating Cash Flow	$338.7M	↓ 65.37%
Investing Cash Flow	$-146.1M	↓ 59.12%
Financing Cash Flow	$-63.8M	↓ 691.55%

	FY22	Y/Y Change
Operating Cash Flow	$556.5M	↑ 75.58%
Investing Cash Flow	$-392.8M	↑ 187.3%
Financing Cash Flow	$-112.2M	↑ 87.86%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$63.5M	↓ 86.52%
Investing Cash Flow	$-267.1M	↑ 0.0%
Financing Cash Flow	$1.0M	↓ 101.15%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$291.6M	↑ 367.2%
Investing Cash Flow	$144.3M	↓ 154.93%
Financing Cash Flow	$2.9M	↑ 185.71%

Genmab A/s Technicals Summary

Sell

Neutral

Buy

Genmab A/s is currently not in a favorable trading position ( SELL ) according to technical analysis indicators.

Genmab A/s (GMAB) Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Genmab A/s	-6.33%	-24.55%	-29.24%	-43.35%	-16.12%
Biontech Se	7.35%	57.95%	33.59%	-31.3%	308.89%
Regeneron Pharmaceuticals, Inc.	-5.9%	-37.18%	-28.8%	8.05%	97.29%
Vertex Pharmaceuticals Incorporated	13.78%	-3.19%	8.71%	82.07%	100.29%
Alnylam Pharmaceuticals, Inc.	16.13%	2.38%	56.77%	86.78%	136.62%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Genmab A/s	19.61	19.61	0.71	1.23	0.15	0.11	NA	502.6
Biontech Se	160.8	NA	0.04	-3.32	-0.02	-0.01	NA	79.73
Regeneron Pharmaceuticals, Inc.	16.89	16.89	1.06	44.96	0.17	0.07	NA	272.04
Vertex Pharmaceuticals Incorporated	32.84	NA	1.15	0.49	-0.03	0.12	NA	60.65
Alnylam Pharmaceuticals, Inc.	NA	NA	-0.49	-0.18	-15.01	-0.03	NA	0.25

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Genmab A/s	Buy	$12.6B	-16.12%	19.61	23.7%
Biontech Se	Buy	$29.0B	308.89%	160.8	-15.36%
Regeneron Pharmaceuticals, Inc.	Buy	$75.1B	97.29%	16.89	33.61%
Vertex Pharmaceuticals Incorporated	Buy	$112.9B	100.29%	32.84	-4.51%
Alnylam Pharmaceuticals, Inc.	Buy	$35.7B	136.62%	NA	-15.86%

About Genmab A/s

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Organization	Genmab A/s
Employees	2635
CEO	Dr. Jan G.J. van de Winkel Ph.D.
Industry	Health Technology

Management People of Genmab A/s

Name	Title
Dr. Jan G.J. van de Winkel Ph.D.	Co-Founder, President & CEO
Mr. Anthony Pagano CPA	Executive VP & CFO
Ms. Birgitte Stephensen M.Sc.	Executive VP & Chief Legal Officer
Mr. Christopher Cozic	Executive VP & Chief People Officer
Dr. Martine J. van Vugt Ph.D.	Executive VP & Chief Strategy Officer
Mr. Martin Schultz	Senior Director of Clinical Operations & Non-Independent Director
Dr. Judith V. Klimovsky M.D.	Executive VP & Chief Development Officer
Dr. Tahamtan Ahmadi	Executive VP, Chief Medical Officer & Head of Experimental Medicines
Dr. Mijke Zachariasse Ph.D.	Senior Director, Head of Antibody Research Materials & Non-Independent Director
Mr. Takahiro Hamatani	Senior Director of Finance Japan & Non-Independent Director

Important FAQs about investing in GMAB Stock from India :

What is Genmab A/s share price today?

Genmab A/s share price today stands at $19.67, Open: $19.78 ; Previous Close: $19.81 ; High: $19.97 ; Low: $19.62 ; 52 Week High: $31.88 ; 52 Week Low: $19.02.

The stock opens at $19.78, after a previous close of $19.81. The stock reached a daily high of $19.97 and a low of $19.62, with a 52-week high of $31.88 and a 52-week low of $19.02.

Can Indians buy Genmab A/s shares?

Yes, Indians can invest in the Genmab A/s (GMAB) from India.

With INDmoney, you can buy Genmab A/s at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Genmab A/s at zero transaction cost.

How can I buy Genmab A/s shares from India?

It is very easy to buy Genmab A/s from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Genmab A/s (GMAB) be purchased?

Yes, you can buy fractional shares of Genmab A/s with INDmoney app.

What are the documents required to start investing in Genmab A/s stocks?

To start investing in Genmab A/s, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.